Phosphatidylinositol 3-Kinase
"Phosphatidylinositol 3-Kinase" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A phosphatidylinositol 3-kinase that catalyzes the conversion of 1-phosphatidylinositol into 1-phosphatidylinositol 3-phosphate.
| Descriptor ID |
D058539
|
| MeSH Number(s) |
D08.811.913.696.620.500.100
|
| Concept/Terms |
Phosphatidylinositol 3-Kinase- Phosphatidylinositol 3-Kinase
- Phosphatidylinositol 3 Kinase
- 1-Phosphatidylinositol 3-Kinase
- 1 Phosphatidylinositol 3 Kinase
|
Below are MeSH descriptors whose meaning is more general than "Phosphatidylinositol 3-Kinase".
Below are MeSH descriptors whose meaning is more specific than "Phosphatidylinositol 3-Kinase".
This graph shows the total number of publications written about "Phosphatidylinositol 3-Kinase" by people in this website by year, and whether "Phosphatidylinositol 3-Kinase" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2010 | 0 | 1 | 1 |
| 2012 | 0 | 2 | 2 |
| 2013 | 0 | 2 | 2 |
| 2014 | 1 | 0 | 1 |
| 2015 | 1 | 1 | 2 |
| 2017 | 1 | 2 | 3 |
| 2019 | 0 | 1 | 1 |
| 2020 | 0 | 1 | 1 |
| 2021 | 0 | 1 | 1 |
| 2022 | 1 | 1 | 2 |
| 2023 | 1 | 0 | 1 |
| 2024 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Phosphatidylinositol 3-Kinase" by people in Profiles.
-
Systematic review of mortality and survival rates for APDS. Clin Exp Med. 2024 Jan 27; 24(1):17.
-
Activated phosphoinositide 3-kinase d syndrome: Update from the ESID Registry and comparison with other autoimmune-lymphoproliferative inborn errors of immunity. J Allergy Clin Immunol. 2023 10; 152(4):984-996.e10.
-
Inhibition of the Phosphatidylinositol-3 Kinase Pathway Using Bimiralisib in Loss-of-Function NOTCH1-Mutant Head and Neck Cancer. Oncologist. 2022 12 09; 27(12):1004-e926.
-
Long Non-Coding RNA uc003jox.1 Promotes Keloid Fibroblast Proliferation and Invasion Through Activating the PI3K/AKT Signaling Pathway. J Craniofac Surg. 2023 Mar-Apr 01; 34(2):556-560.
-
Targeting the PI3K Pathway in Gynecologic Malignancies. Curr Oncol Rep. 2022 12; 24(12):1669-1676.
-
Management of hormone receptor-positive, human epidermal growth factor 2-negative metastatic breast cancer. Breast Cancer Res Treat. 2021 Nov; 190(2):189-201.
-
Resistance Mutations to BTK Inhibitors Originate From the NF-?B but Not From the PI3K-RAS-MAPK Arm of the B Cell Receptor Signaling Pathway. Front Immunol. 2021; 12:689472.
-
Targeting phosphatidylinositol 3 kinase-? and -d for Bruton tyrosine kinase resistance in diffuse large B-cell lymphoma. Blood Adv. 2020 09 22; 4(18):4382-4392.
-
Endogenous YAP1 activation drives immediate onset of cervical carcinoma in situ in mice. Cancer Sci. 2020 Oct; 111(10):3576-3587.
-
Somatic Gain of KRAS Function in the Endothelium Is Sufficient to Cause Vascular Malformations That Require MEK but Not PI3K Signaling. Circ Res. 2020 08 28; 127(6):727-743.